InFLUenza and the HEART An Investigation Into the Acute and Lasting Cardiac Effects of Influenza Infection (FluHeart)

Influenza and the Heart: An Investigation Into the Acute and Lasting Cardiac Effects of Influenza Infection

"Influenza and the Heart: An investigation into the acute and lasting cardiac effects of influenza infection" the investigators aim to assess the mechanisms for cardiovascular disease in patients suffering an acute influenza infection. The project will be carried out by creating a prospective clinical cohort study of consecutive patients hospitalized at Herlev & Gentofte University Hospital with a laboratory confirmed influenza.

Study Overview

• Status: Completed
• Conditions: Influenza; Cardiovascular Complication

• Study Type: Observational
• Enrollment (Actual): 241

Contacts and Locations

Study Locations

• Denmark
  • Copenhagen, Denmark, 2900
    • Herlev & Gentofte Hospital
  • Hellerup, Denmark, 2900
    • Cardiovascular Non-Invasive Imaging Research Laboratory, department of Cardiology, Herlev & Gentofte Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: N/A

• Sampling Method: Non-Probability Sample

Study Population

Hospitalized patients with laboratory confirmed influenza

Description

Inclusion Criteria:

• All patients hospitalized at Herlev & Gentofte University Hospital with a laboratory-confirmed diagnosis of influenza
• > 18 years of age

Exclusion Criteria:

• Persons not able to cooperate
• Persons unable to understand and sign "informed consent"
• Pregnancy
• Persons simultaneously positive with COVID-19

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of patients developing cardiovascular complications	Including new-onset heart failure, worsening of current heart failure, acute myocardial infarction, and cardiac arrest	3 years
Number of patients developing in-hospital mortality		3 years
Rate of cardiac dysfunction	Defined by impaired echocardiographic parameters and elevated cardiac biomarkers - NT - pro - BNP annd hs - TNT	3 years
Prevalence of elevated biomarkers of infection/inflammation	Prevalence of elevated biomarkers of infection/inflammation and it association with cardiac dysfunction	3 years
Rate of pulmonary embolisms diagnosed with CT thorax angiography		3 years

Collaborators and Investigators

• Sponsor: University Hospital, Gentofte, Copenhagen

Study record dates

Study Major Dates

• Study Start (Actual): January 1, 2022
• Primary Completion (Actual): May 1, 2024
• Study Completion (Actual): June 1, 2024

Study Registration Dates

• First Submitted: October 6, 2021
• First Submitted That Met QC Criteria: October 6, 2021
• First Posted (Actual): October 20, 2021

Study Record Updates

• Last Update Posted (Actual): May 4, 2026
• Last Update Submitted That Met QC Criteria: May 1, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Respiratory Tract Infections; Infections; Orthomyxoviridae Infections; RNA Virus Infections; Virus Diseases; Respiratory Tract Diseases; Influenza, Human
• Other Study ID Numbers: H-21011835

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No